Biomarkers of regimen-related mucosal injury

Cancer Treatment Reviews

Volumn 37, Issue 6, 2011, Pages 487-493

  Gibson, Rachel J ^a   Bowen, Joanne M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Biomarkers; Mucosal injury; Mucositis; Toxicity

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CITRULLINE; CYTOKINE; LACTOFERRIN; LEUKOTRIENE; PROHEPCIDIN; THROMBOXANE; TRANSFERRIN;

ANALYTIC METHOD; BREATH ANALYSIS; CANCER RADIOTHERAPY; EOSINOPHIL; EPITHELIUM CELL; HEMATOLOGIC MALIGNANCY; HUMAN; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MUCOSAL INJURY; NONHUMAN; OXIDATIVE STRESS; REVIEW; SUCROSE BREATH TEST; SUGAR PERMEABILITY TEST; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HUMANS; MUCOSITIS; MUCOUS MEMBRANE; NEOPLASMS; PROGNOSIS;

EID: 79960995795     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.05.007     Document Type: Review

References (74)

1. Keefe D.M., Schubert M.M., Elting L.S., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007, 109(5):820-831.
2. Capp A., Inostroza-Ponta M., Bill D., et al. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol 2009, 90:400-407.
3. Keefe D.M., Brealey J., Goland G.J., Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000, 47(5):632-637.
4. Rubenstein E.B., Peterson D.E., Schubert M.M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004, 100(9 suppl):2026-2046.
5. Sonis S.T., Elting L.S., Keefe D., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004, 100(9 Suppl):1995-2025.
6. Saltz L., Shimada Y., Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 1996, 32A(Suppl 3):S24-S31.
7. Saltz L.B. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003, 1(1):35-46. discussion 38-41, 5-6.
8. Viele C.S. Overview of chemotherapy-induced diarrhea. Semin Oncol Nurs 2003, 19(4 Suppl. 3):2-5.
9. Wadler S., Benson A.B., Engelking C., et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998, 16(9):3169-3178.
10. Richardson G., Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007, 13(4):181-198.
11. Peterson D.E., Cariello A. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol 2004, 31(3 Suppl. 8):35-44.
12. Scarantino C., LeVeque F., Swann R.S., et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol 2006, 4(5):252-258.
13. Sung L., Tomlinson G.A., Greenberg M.L., et al. Validation of the oral mucositis assessment scale in pediatric cancer. Pediatr Blood Cancer 2007, 49(2):149-153.
14. Worthington H.V., Clarkson J.E., Bryan G., et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2010, 12:CD000978.
15. Clarkson J.E., Worthington H.V., Furness S., McCabe M., Khalid T., Meyer S. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2010, (8):CD001973.
16. Beaven A.W., Shea T.C. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs Today (Barc) 2007, 43(7):461-473.
17. Buchsel P.C. Polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin Drug Metab Toxicol 2008, 4(11):1449-1454.
18. Kouloulias V., Kouvaris J., Mystakidou K., Kelekis N. Prevention of acute radiation-induced rectal toxicity by amifostine: efficacy and evaluation of objective and subjective endpoints for radiation therapy-induced mucositis. Support Cancer Ther 2006, 4(1):23-29.
19. Lutgens L.C., Blijlevens N.M., Deutz N.E., Donnelly J.P., Lambin P., de Pauw B.E. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 2005, 103(1):191-199.
20. Windmueller H.G., Spaeth A.E. Source and fate of circulating citrulline. Am J Physiol 1981, 241:E473-E480. Endocrinol Metab. 5.
21. Rabier D., Kamoun P. Metabolism of citrulline in man. Amino Acids 1995, 9:299-316.
22. Blijlevens N.M., Lutgens L.C., Schattenberg A.V., Donnelly J.P. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004, 34(3):193-196.
23. Jianfeng G., Weiming Z., Ning L., Fangnan L., Li T., Nan L., et al. Serum citrulline is a simple quantitative marker for small intestinal enterocytes mass and absorption function in short bowel patients. J Surg Res 2005, 127(2):177-182.
24. Lutgens L.C., Deutz N., Granzier-Peeters M., et al. Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys 2004, 60(1):275-285.
25. Lutgens L.C., Deutz N.E., Gueulette J., et al. Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys 2003, 57(4):1067-1074.
26. Lutgens L., Lambin P. Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline. World J Gastroenterol 2007, 13(22):3033-3042.
27. Wedlake L., McGough C., Hackett C., et al. Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa?. Aliment Pharmacol Ther 2008, 27(10):980-987.
28. Fijlstra M., Rings E.H.H.M., Verkade H.J., van Dijk T.H., Kamps W.A., Tissing W.J.R. Lactose maldigestion during methotrexate-induced gastrointestinal mucositis in a rat model. Am J Physiol Gastrointest Liver Physiol 2011, 300:G238-G291.
29. van Vliet M.J., Tissing W.J., Rings E.H., et al. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 2009, 53(7):1188-1194.
30. Crenn P., Messing B., Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 2008, 27(3):328-339.
31. Keefe D.M., Gibson R.J. Sucrose breath testing and intestinal mucositis. Cancer Biol Ther 2006, 5(9):1196-1198.
32. Tooley K.L., Howarth G.S., Butler R.N. Mucositis and non-invasive markers of small intestinal function. Cancer Biol Ther 2009, 8(9):753-758.
33. Ziegler T.R. Glutamine supplementation in bone marrow transplantation. Br J Nutr 2002, 87(Suppl 1):S9-S15.
34. Boukhettala N., Leblond J., Claeyssens S., et al. Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake. Am J Physiol Endocrinol Metab 2009, 296(1):E182-E190.
35. Konikoff M.R., Denson L.A. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12(6):524-534.
36. Costa F., Mumolo M.G., Ceccarelli L., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54(3):364-368.
37. Foell D., Wittkowski H., Ren Z., et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008, 216(2):183-192.
38. Roseth A.G. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 2003, 35(9):607-609.
39. Costa F., Mumolo M.G., Bellini M., et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003, 35(9):642-647.
40. Thjodleifsson B., Sigthorsson G., Cariglia N., et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn'ss disease relatives?. Gastroenterology 2003, 124(7):1728-1737.
41. Richter K.K., Fagerhol M.K., Carr J.C., Winkler J.M., Sung C.C., Hauer-Jensen M. Association of granulocyte transmigration with structural and cellular parameters of injury in experimental radiation enteropathy. Radiat Oncol Invest 1997, 5(6):275-282.
42. Clarke J.M., Pelton N.C., Bajka B.H., Howarth G.S., Read L.C., Butler R.N. Use of the 13C-sucrose breath test to assess chemotherapy-induced small intestinal mucositis in the rat. Cancer Biol Ther 2006, 5(1):34-38.
43. Pelton N.S., Tivey D.R., Howarth G.S., Davidson G.P., Butler R.N. A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol 2004, 39(10):1015-1016.
44. Tooley K.L., Saxon B.R., Webster J., et al. A novel non-invasive biomarker for assessment of small intestinal mucositis in children with cancer undergoing chemotherapy. Cancer Biol Ther 2006, 5(10):1275-1281.
45. Logan R.M., Stringer A.M., Bowen J.M., Gibson R.J., Sonis S.T., Keefe D.M. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008, 7(7):1139-1145.
46. Heney D., Lewis I.J., Evans S.W., Banks R., Bailey C.C., Whicher J.T. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992, 165(5):886-890.
47. Engel A., Mack E., Kern P., Kern W.V. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection 1998, 26(4):213-221.
48. Lehrnbecher T., Venzon D., de Haas M., Chanock S.J., Kuhl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999, 29(2):414-419.
49. Badiei Z., Khalesi M., Alami M.H., et al. Risk Factors associated with life-threatening infections in children with febrile neutropenia: a data mining approach. J Pediatr Hematol Oncol 2011, 33(1):e9-e12.
50. Engelhard D., Elishoov H., Or R., et al. Cytosine arabinodise as a major risk factor for Streptococcs viridians septicaemia following bone marrow transplantation: a 5year prospective study. Bone marrow transplant 1995, 16(4):565-570.
51. Blijlevens N., Logan R.M., Netea M.G. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicro Chemo 2009, 63(Suppl. 1):i36-i40.
52. Foell D., Wittkowski H., Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009, 58(6):859-868.
53. Fleischhack G., Kambeck I., Cipic D., Hasan C., Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000, 111(4):1093-1102.
54. Cengiz M., Akbulut S., Atahan I.L., Grigsby P.W. Acute phase response during radiotherapy. Int J Radiat Oncol Biol Phys 2001, 49(4):1093-1096.
55. Ki Y., Kim W., Nam J., Kim D., Park D., Kim D. C-reactive protein levels and radiation-induced mucositis in patients with head-and-neck cancer. Int J Rad Oncol Biol Phys 2009, 75(2):393-398.
56. Koc M., Taysi S., Sezen O., Bakan N. Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 2003, 26(10):1494-1497.
57. Bowen J.M., Newbold K., Blake P., et al. Do serum levels of eosinophil granule-derived protein change in patients undergoing pelvic radiotherapy?. Clin Oncol (R Coll Radiol) 2005, 17(5):382-384.
58. Wakabayashi H., Yamauchi K., Takase M. Lactoferrin research, technology and applications. Int Dairy J 2006, 16:1241-1251.
59. van't Land B., van Beek N.M., van den Berg J.J., M'Rabet L. Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation. Dig Dis Sci 2004, 49(3):425-433.
60. Clarke J.M., Edwards B.G., Srpek L., Regester G.O. Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster. Oral Oncol 1999, 35:197-202.
61. van der Sluys Veer A., Biemond I., Verspaget H.W., Lamers C.B.H.W. Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol 1999, 34(Supp 230):106-110.
62. Walker T.R., Land M.L., Kartashov A., et al. Faecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:414-422.
63. Walker T.R., Sandborn W.J., Boone J.H., Sisco D., Lyerly D.M., Rufo P.A. Fecal lactoferrin measurements are useful in the internal assessment of patients with active and inactive inflammatory bowel disease. Am J Gastroenterol 2003, 98(9 Suppl):S246.
64. Richter K.K., Wang J., Fagerhol M.K., Hauer-Jensen M. Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine. Radiother Oncol 2001, 59(1):81-85.
65. Larsen A., Bjorge B., Klementsen B., et al. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncol 2007, 46(5):639-650.
66. Menzies I.S., Pounder R., Heyer S., et al. Abnormal intestinal permeability to sugars in villous atrophy. Lancet 1979, 2:1107-1109.
67. Cummins A.G., Penttila I.A., Labrooy J.T., Robb T.A., DAvidson G.P. Recovery of the small intestine in coeliac disease on a gluten free diet: changes in intestinal permeability, small bowel morphology and T-cell activity. J Gastroenterology Hepatol 1991, 6:53-57.
68. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004, 11:251-254.
69. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
70. Christiansen H., Saile B., Hermann R.M., et al. Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer. J Cancer Res Clin Oncol 2007, 133:297-304.
71. Cole A.T., Slater K., Sokal M., Hawkey C.J. In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis. Gut 1993, 34:1210-1214.
72. Park M.-Y., Kwan H.J., Sung M.K. Dietary aloinm aloesin or aloe-gel exerts anti-inflammatory activity in a rat colitis model. Life Sci 2011, 88(11-12):486-492.
73. Pirmohamed M. Acceptance of biomarker-based tests for application in clinical practice. criteria and obstacles. Clin Pharmacol Ther 2010, 88(6):862-866.
74. Dakna M., Keith H., Kalousis A., et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinf 2010, 11(1):594.